Company
Arthrosi Therapeutics
Arthrosi Therapeutics is a clinical-stage biotech company focused on the development of therapy for gout and chronic kidney disease.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- Arthrosi Therapeutics
Claim, correct or request removal
Record updated 28 September 2026
About
a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients
Funding snapshot
- Total raised
- $153MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series D+, $153M2025-10-14
Funding rounds
- Series D+
- $153M2025-10-14, Company stated
- Round, 2025
- $60.9M2025-06-06, SEC form D sold, 13 investors
- Round, 2023
- $7M2023-09-05, SEC form D sold, 1 investor
- Round, 2023
- $15M2023-02-07, SEC form D sold, 2 investors
- Round, 2021
- $26M2021-08-16, SEC form D sold, 2 investors
- Round, 2021
- $220K2021-08-02, SEC form D sold, 1 investor
- Round, 2020
- $8.5M2020-05-20, SEC form D sold, 3 investors
- Round, 2018
- $11M2018-10-29, SEC form D sold, 3 investors
- Round, 2018
- $4.3M2018-01-24, SEC form D sold, 3 investors
Products
- Other
- pozdeutinurad (AR882)
Exit
- Acquisition
- 2025-12-15
Loading relationship preview